Reuters logo
BRIEF-Genmab says U.S. FDA approves darzalex in combination with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma
2017年6月16日 / 下午5点53分 / 5 个月前

BRIEF-Genmab says U.S. FDA approves darzalex in combination with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma

June 16 (Reuters) - Genmab A/S

* Genmab announces u.s. fda approval of darzalex(daratumumab) in combination with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma

* Genmab - will receive milestone payments totaling $25 million from Janssen in connection with approval & first commercial sale of darzalex under newly expanded label

* Genmab - approval and related milestones do not impact financial guidance issued by Genmab on May 10, 2017 Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below